Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A-related epilepsy and/or neurodevelopmental disorders.
developmental and epileptic encephalopathy
function of variant
heterogeneity
phenotypes
sodium channel blockers
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
revised:
08
04
2024
received:
13
11
2023
accepted:
08
04
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
28
5
2024
Statut:
aheadofprint
Résumé
We aimed to develop consensus for diagnosis/management of SCN8A-related disorders. Utilizing a modified Delphi process, a global cohort of experienced clinicians and caregivers provided input on diagnosis, phenotypes, treatment, and management of SCN8A-related disorders. A Core Panel (13 clinicians, one researcher, six caregivers), divided into three subgroups (diagnosis/phenotypes, treatment, comorbidities/prognosis), performed a literature review and developed questions for the modified Delphi process. Twenty-eight expert clinicians, one researcher, and 13 caregivers from 16 countries participated in the subsequent three survey rounds. We defined consensus as follows: strong consensus, ≥80% fully agree; moderate consensus, ≥80% fully/partially agree, <10% disagree; and modest consensus, 67%-79% fully/partially agree, <10% disagree. Early diagnosis is important for long-term clinical outcomes in SCN8A-related disorders. There are five phenotypes: three with early seizure onset (severe developmental and epileptic encephalopathy [DEE], mild/moderate DEE, self-limited (familial) infantile epilepsy [SeL(F)IE]) and two with later/no seizure onset (neurodevelopmental delay with generalized epilepsy [NDDwGE], NDD without epilepsy [NDDwoE]). Caregivers represented six patients with severe DEE, five mild/moderate DEE, one NDDwGE, and one NDDwoE. Phenotypes vary by age at seizures/developmental delay onset, seizure type, electroencephalographic/magnetic resonance imaging findings, and first-line treatment. Gain of function (GOF) versus loss of function (LOF) is valuable for informing treatment. Sodium channel blockers are optimal first-line treatment for GOF, severe DEE, mild/moderate DEE, and SeL(F)IE; levetiracetam is relatively contraindicated in GOF patients. First-line treatment for NDDwGE is valproate, ethosuximide, or lamotrigine; sodium channel blockers are relatively contraindicated in LOF patients. This is the first-ever global consensus for the diagnosis and treatment of SCN8A-related disorders. This consensus will reduce knowledge gaps in disease recognition and inform preferred treatment across this heterogeneous disorder. Consensus of this type allows more clinicians to provide evidence-based care and empowers SCN8A families to advocate for their children.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : International SCN8A Alliance
Informations de copyright
© 2024 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Veeramah KR, O'Brien JE, Meisler MH, Cheng X, Dib‐Hajj SD, Waxman SG, et al. De novo pathogenic SCN8A mutation identified by whole‐genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet. 2012;90(3):502–510. https://doi.org/10.1016/j.ajhg.2012.01.006
Trudeau MM. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet. 2006;43(6):527–530. https://doi.org/10.1136/jmg.2005.035667
Larsen J, Carvill GL, Gardella E, Kluger G, Schmiedel G, Barisic N, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology. 2015;84(5):480–489. https://doi.org/10.1212/WNL.0000000000001211
Wagnon JL, Barker BS, Ottolini M, Park Y, Volkheimer A, Valdez P, et al. Loss‐of‐function variants of SCN8A in intellectual disability without seizures. Neurol Genet. 2017;3(4):e170. https://doi.org/10.1212/NXG.0000000000000170
Wagnon JL, Mencacci NE, Barker BS, Wengert ER, Bhatia KP, Balint B, et al. Partial loss‐of‐function of sodium channel SCN8A in familial isolated myoclonus. Hum Mutat. 2018;39(7):965–969. https://doi.org/10.1002/humu.23547
Gardella E, Marini C, Trivisano M, Fitzgerald MP, Alber M, Howell KB, et al. The phenotype of SCN8A developmental and epileptic encephalopathy. Neurology. 2018;91(12):e1112–e1124. https://doi.org/10.1212/WNL.0000000000006199
Gardella E, Møller RS. Phenotypic and genetic spectrum of SCN8A‐related disorders, treatment options, and outcomes. Epilepsia. 2019;60(Suppl 3):S77–S85. https://doi.org/10.1111/epi.16319
Johannesen KM, Gardella E, Encinas AC, Lehesjoki AE, Linnankivi T, Petersen MB, et al. The spectrum of intermediate SCN8A‐related epilepsy. Epilepsia. 2019;60(5):830–844. https://doi.org/10.1111/epi.14705
Johannesen KM, Liu Y, Koko M, Gjerulfsen CE, Sonnenberg L, Schubert J, et al. Genotype‐phenotype correlations in SCN8A‐related disorders reveal prognostic and therapeutic implications. Brain J Neurol. 2022;145(9):2991–3009. https://doi.org/10.1093/brain/awab321
Peng BW, Tian Y, Chen L, Duan LF, Wang XY, Zhu HX, et al. Genotype‐phenotype correlations in SCN8A‐related epilepsy: a cohort study of Chinese children in southern China. Brain J Neurol. 2022;145(4):e24–e27. https://doi.org/10.1093/brain/awac038
Hack JB, Horning K, Juroske Short DM, Schreiber JM, Watkins JC, Hammer MF. Distinguishing loss‐of‐function and gain‐of‐function SCN8A variants using a random Forest classification model trained on clinical features. Neurol Genet. 2023;9(3):e200060. https://doi.org/10.1212/NXG.0000000000200060
Lemke JR. Predicting incidences of neurodevelopmental disorders. Brain. 2020;143(4):1046–1048. https://doi.org/10.1093/brain/awaa079
Hammer MF, Xia M, Schreiber JM. SCN8A‐related epilepsy and/or neurodevelopmental disorders. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2016 [updated April 6, 2023].
Mercimek‐Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, Donner EJ, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia. 2015;56(5):707–716. https://doi.org/10.1111/epi.12954
Butler KM, da Silva C, Shafir Y, Weisfeld‐Adams JD, Alexander JJ, Hegde M, et al. De novo and inherited SCN8A epilepsy mutations detected by gene panel analysis. Epilepsy Res. 2017;129:17–25. https://doi.org/10.1016/j.eplepsyres.2016.11.002
Costain G, Cordeiro D, Matviychuk D, Mercimek‐Andrews S. Clinical application of targeted next‐generation sequencing panels and whole exome sequencing in childhood epilepsy. Neuroscience. 2019;418:291–310. https://doi.org/10.1016/j.neuroscience.2019.08.016
Salinas V, Martínez N, Maturo JP, Rodriguez‐Quiroga SA, Zavala L, Medina N, et al. Clinical next generation sequencing in developmental and epileptic encephalopathies: diagnostic relevance of data re‐analysis and variants re‐interpretation. Eur J Med Genet. 2021;64(12):104363. https://doi.org/10.1016/j.ejmg.2021.104363
Kong W, Zhang Y, Gao Y, Liu X, Gao K, Xie H, et al. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia. 2015;56(3):431–438. https://doi.org/10.1111/epi.12925
Boerma RS, Braun KP, van den Broek MPH, van Berkestijn FM, Swinkels ME, Hagebeuk EO, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A‐related epilepsy: a molecular neuropharmacological approach. Neurother J Am Soc Exp Neurother. 2016;13(1):192–197. https://doi.org/10.1007/s13311‐015‐0372‐8
Schreiber JM, Tochen L, Brown M, Evans S, Ball LJ, Bumbut A, et al. A multi‐disciplinary clinic for SCN8A‐related epilepsy. Epilepsy Res. 2020;159:106261. https://doi.org/10.1016/j.eplepsyres.2019.106261
Gardella E, Becker F, Mueller RS, Schubert J, Lemke JR, Larsen LH, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol. 2016;79(3):428–436. https://doi.org/10.1002/ana.24580
Conecker G. Global consensus on comorbidities and prognosis across five phenotypes of SCN8A‐related epilepsy and/or neurodevelopmental disorders. Note: companion manuscript proposed for publication at the same time as this manuscript; citation will be updated at the time of publication.
Andrews JG, Galindo MK, Hack JB, Watkins JC, Conecker GA, Hammer MF. The international SCN8A patient registry: a scientific resource to advance the understanding and treatment of a rare pediatric neurodevelopmental syndrome. J Registry Manag. 2023;50(1):4–10.
Chung KM, Hack J, Andrews J, Galindo‐Kelly M, Schreiber J, Watkins J, et al. Clinical severity is correlated with age at seizure onset and biophysical properties of recurrent gain of function variants associated with SCN8A‐related epilepsy. Epilepsia. 2023;64(12):3365–3376. https://doi.org/10.1111/epi.17747
Encinas AC, Moore IKM, Watkins JC, Hammer MF. Influence of age at seizure onset on the acquisition of neurodevelopmental skills in an SCN8A cohort. Epilepsia. 2019;60(8):1711–1720. https://doi.org/10.1111/epi.16288
Talwar D, Hammer MF. SCN8A epilepsy, developmental encephalopathy, and related disorders. Pediatr Neurol. 2021;122:76–83. https://doi.org/10.1016/j.pediatrneurol.2021.06.011
Dalkey N, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci. 1963;9:458–467.
Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations from a north American consensus panel. Pediatr Neurol. 2017;68:18–34.e3. https://doi.org/10.1016/j.pediatrneurol.2017.01.025
Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, et al. International consensus on diagnosis and management of dravet syndrome. Epilepsia. 2022;63(7):1761–1777. https://doi.org/10.1111/epi.17274
Smith L, Malinowski J, Ceulemans S, Peck K, Walton N, Sheidley BR, et al. Genetic testing and counseling for the unexplained epilepsies: an evidence‐based practice guideline of the National Society of genetic counselors. J Genet Couns. 2023;32(2):266–280. https://doi.org/10.1002/jgc4.1646
Wang J, Gao H, Bao X, Zhang Q, Li J, Wei L, et al. SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures. BMC Med Genet. 2017;18(1):104. https://doi.org/10.1186/s12881‐017‐0460‐1
Ohba C, Kato M, Takahashi S, Lerman‐Sagie T, Lev D, Terashima H, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia. 2014;55(7):994–1000. https://doi.org/10.1111/epi.12668
Anand G, Collett‐White F, Orsini A, Thomas S, Jayapal S, Trump N, et al. Autosomal dominant SCN8A mutation with an unusually mild phenotype. Eur J Paediatr Neurol. 2016;20(5):761–765. https://doi.org/10.1016/j.ejpn.2016.04.015
Parrini E, Marini C, Mei D, Galuppi A, Cellini E, Pucatti D, et al. Diagnostic targeted resequencing in 349 patients with drug‐resistant pediatric epilepsies identifies causative mutations in 30 different genes: HUMAN MUTATION. Hum Mutat. 2017;38(2):216–225. https://doi.org/10.1002/humu.23149
Xiao Y, Xiong J, Liu L, Li J, Li X, Luo H, et al. Early‐onset epileptic encephalopathy with de novo SCN8A mutation. Epilepsy Res. 2018;139:9–13. https://doi.org/10.1016/j.eplepsyres.2017.10.017
Lindy AS, Stosser MB, Butler E, Downtain‐Pickersgill C, Shanmugham A, Retterer K, et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia. 2018;59(5):1062–1071. https://doi.org/10.1111/epi.14074
Arafat A, Fei Y. Undefined early onset epileptic encephalopathy: next generation sequencing and phenotype expansion, an approach towards a better tomorrow. J Neurol Sci. 2017;381:181. https://doi.org/10.1016/j.jns.2017.08.522
Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1349–1397. https://doi.org/10.1111/epi.17239
Wilmshurst JM, Gaillard WD, Vinayan KP, Tsuchida TN, Plouin P, Van Bogaert P, et al. Summary of recommendations for the management of infantile seizures: task force report for the ILAE Commission of Pediatrics. Epilepsia. 2015;56(8):1185–1197. https://doi.org/10.1111/epi.13057
Aledo‐Serrano Á, Cabal‐Paz B, Gardella E, Gómez‐Porro P, Martínez‐Múgica O, Beltrán‐Corbellini A, et al. Effect of fenfluramine on seizures and comorbidities in SCN8A‐developmental and epileptic encephalopathy: a case series. Epilepsia Open. 2022;7(3):525–531. https://doi.org/10.1002/epi4.12623
Johnson J, Focken T, Khakh K, Tari PK, Dube C, Goodchild SJ, et al. NBI‐921352, a first‐in‐class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain‐of‐function mice, and wild‐type mice and rats. elife. 2022;11:e72468. https://doi.org/10.7554/eLife.72468
Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, et al. The novel persistent sodium current inhibitor PRAX‐562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia. 2022;63(3):697–708. https://doi.org/10.1111/epi.17149
Winczewska‐Wiktor A, Hirschfeld AS, Badura‐Stronka M, Komasińska‐Piotrowska P, Steinborn B. Analysis of factors that may affect the effectiveness of ketogenic diet treatment in pediatric and adolescent patients. J Clin Med. 2022;11(3):606. https://doi.org/10.3390/jcm11030606
Kim HJ, Yang D, Kim SH, Kim B, Kim HD, Lee JS, et al. Genetic and clinical features of SCN8A developmental and epileptic encephalopathy. Epilepsy Res. 2019;158:106222. https://doi.org/10.1016/j.eplepsyres.2019.106222
Podkorytova I, Hays R, Perven G, Alick LS. Epilepsy surgery in patient with monogenic epilepsy related to SCN8A mutation. Epilepsy Behav Rep. 2022;18:100536. https://doi.org/10.1016/j.ebr.2022.100536
Albert DVF, Moreland JJ, Salvator A, Moore‐Clingenpeel M, Haridas B, Cole JW, et al. Seizure action plans for pediatric patients with epilepsy: a randomized controlled trial. J Child Neurol. 2019;34(11):666–673. https://doi.org/10.1177/0883073819846810
Neville KL, McCaffery H, Baxter Z, Shellhaas RA, Fedak Romanowski EM. Implementation of a standardized seizure action plan to improve communication and parental education. Pediatr Neurol. 2020;112:56–63. https://doi.org/10.1016/j.pediatrneurol.2020.04.005
Penovich P, Glauser T, Becker D, Patel AD, Sirven J, Long L, et al. Recommendations for development of acute seizure action plans (ASAPs) from an expert panel. Epilepsy Behav EB. 2021;123:108264. https://doi.org/10.1016/j.yebeh.2021.108264
Patel AD, Becker DA. Introduction to use of an acute seizure action plan for seizure clusters and guidance for implementation. Epilepsia. 2022;63(Suppl 1):S25–S33. https://doi.org/10.1111/epi.17344